Monoclonal antibody B43 Genistein-conjugate

N/A

Report date: 2022/03/09 11:02:50

Base Information

Drug NameMonoclonal antibody B43 Genistein-conjugate
Drug Alias NameB43-Genistein conjugateB43-GenisteinB43-GenMonoclonal antibody B43-Gen
ClassificationBiologics > Protein drugs > Immunoglobulin > Antibody > Antibody conjugate > Antibody drug conjugate (ADC)
Mechanisms of ActionB-lymphocyte antigen CD19 inhibitorsReceptor protein-tyrosine kinase modulators
TargetsB-lymphocyte antigen CD19Receptor protein-tyrosine kinase
Therapy Area/IndicationsLymphoma, Non-HodgkinPrecursor Cell Lymphoblastic Leukemia-Lymphoma
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryN/A
CombinationsNo
Global Highest StatusDiscontinued (Phase 1 Clinical)
Highest Status in ChinaN/A
Originator CompaniesUniversity Of MinnesotaBristol-Myers Squibb Company
China Registration ClassN/A

Develop Information

Active CompaniesN/A
Inactive CompaniesUniversity Of MinnesotaBristol-Myers Squibb Company
Active IndicationsN/A
Inactive IndicationsLymphoma, Non-HodgkinPrecursor Cell Lymphoblastic Leukemia-Lymphoma

Other Information

ATC CodeN/A
Related LinksN/A